

CORRECTION

Open Access



Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Chen-Hua Yan^{1,2}, Yu Wang^{1,2}, Jing-Zhi Wang¹, Yu-Hong Chen¹, Yao Chen¹, Feng-rong Wang¹, Yu-Qian Sun¹, Xiao-Dong Mo¹, Wei Han¹, Huan Chen¹, Xiao-hui Zhang^{1,2}, Lan-Ping Xu¹, Kai-Yan Liu^{1,2} and Xiao-Jun Huang^{1,2*}

Correction to: J Hematol Oncol (2016) 9:87
<https://doi.org/10.1186/s13045-016-0319-5>

The original article [1] contains two errors in the MRD Testing sub-section of the Methods:

- 1) The description, "...by four-color flow cytometry (FCM)" was incorrect. The correct description should be "...by eight-color flow cytometry (FCM)".
- 2) The description, "LAIPs were detected by four-color FCM" was incorrect. The correct description should be "LAIPs were detected by eight-color FCM".

Received: 26 February 2019 Accepted: 27 February 2019
Published online: 05 March 2019

Reference

1. Yan C-H, et al. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. *J Hematol Oncol.* 2016;9:87. <https://doi.org/10.1186/s13045-016-0319-5>.

* Correspondence: huangxiaojun@bjmu.edu.cn

¹Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, Xi Zhimen South Street No. 11, Beijing 100044, China

²Collaborative Innovation Center of Hematology, Xi Zhimen South Street No. 11, Beijing 100044, China

